Biogen Inc (BIIB) : California State Teachers Retirement System reduced its stake in Biogen Inc by 1.97% during the most recent quarter end. The investment management company now holds a total of 464,261 shares of Biogen Inc which is valued at $149,185,630 after selling 9,316 shares in Biogen Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Biogen Inc makes up approximately 0.31% of California State Teachers Retirement System’s portfolio.
Other Hedge Funds, Including , Shelton Capital Management boosted its stake in BIIB in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 15,975 shares of Biogen Inc which is valued at $5,133,407. Biogen Inc makes up approx 0.45% of Shelton Capital Management’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in BIIB by selling 5,529 shares or 10.74% in the most recent quarter. The Hedge Fund company now holds 45,943 shares of BIIB which is valued at $13,320,254. Biogen Inc makes up approx 0.11% of Public Employees Retirement Association Of Colorado’s portfolio. Donald L. Hagan sold out all of its stake in BIIB during the most recent quarter. The investment firm sold 80 shares of BIIB which is valued $23,022.Cue Financial Group boosted its stake in BIIB in the latest quarter, The investment management firm added 540 additional shares and now holds a total of 1,832 shares of Biogen Inc which is valued at $460,180. Biogen Inc makes up approx 0.38% of Cue Financial Group’s portfolio.Lgt Capital Partners Ltd. boosted its stake in BIIB in the latest quarter, The investment management firm added 25,150 additional shares and now holds a total of 84,230 shares of Biogen Inc which is valued at $21,157,734. Biogen Inc makes up approx 3.59% of Lgt Capital Partners Ltd.’s portfolio.
Biogen Inc closed down -6.78 points or -2.11% at $314.56 with 20,02,341 shares getting traded on Thursday. Post opening the session at $320.15, the shares hit an intraday low of $314.01 and an intraday high of $320.45 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.
Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.